Status:
COMPLETED
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
Lead Sponsor:
Progenics Pharmaceuticals, Inc.
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistan...
Eligibility Criteria
Inclusion
- A diagnosis of progressive, castration-resistant, metastatic prostate cancer.
- Prior chemotherapy regimens, one of which contains taxane.
- Eastern Cooperative Oncology Group status of 0 or 1
Exclusion
- Clinically significant cardiac disease or severe debilitation pulmonary disease
- Evidence of an active infection requiring ongoing antibiotic therapy
- Any prior treatment with any other therapy targeting PSMA
- History of drug and/or alcohol abuse
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT01414283
Start Date
October 1 2008
End Date
September 1 2013
Last Update
November 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Progenics Pharmaceuticals, Inc.
Tarrytown, New York, United States, 10591